Report of Foreign Issuer (6-k)
September 13 2016 - 2:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2016.
Commission File Number:
000-53805
Intellipharmaceutics
International Inc.
(Translation of registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W
5X2
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ x ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Note:
Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Note:
Regulation S-T Rule 101(b)(7) only permits the submission
in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish
and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are
traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Only the statements in respect of
the anticipated timing of the filing of the Rexista® XR (oxycodone hydrochloride) new drug application currently expected to
be filed by Intellipharmaceutics International Inc. (the “registrant”) during its fiscal fourth quarter of 2016 set
forth in the attached exhibit 99.1 shall be incorporated by reference into the registrant's effective Registration Statements on
Form F-3, as amended and supplemented (Registration Statement Nos. 333-172796 and 333-196112), filed with the Securities and Exchange
Commission, from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed
or furnished by the registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934.
Except
for the foregoing, no other document or portion of document furnished with this Form 6-K is incorporated by reference into the
above-referenced Registration Statements.
Any projections and/or illustrative examples, as the case may be,
contained in exhibit 99.1 are included solely to provide certain overview information concerning the variable potential financial
results of drug commercialization in this industry sector when certain assumptions are used, and how those results could impact
the potential future operating results of the registrant. No assurance can be made that such results will be achieved. The registrant
may conduct its business in a manner different from that set forth in the assumptions, as changing circumstances may require. Actual
results of operations are likely to vary from the projections and the variations may be material and adverse. The projections should
not be regarded as a representation or prediction that the registrant will achieve or is likely to achieve any particular results.
Without limiting the generality of the foregoing, no assurance can be given as to whether or when the registrant will receive regulatory
approval for any of the registrant’s product candidates.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Intellipharmaceutics International
Inc.
(Registrant)
|
Date: September 13, 2016
|
|
/s/ Domenic Della Penna
Domenic Della Penna
Chief Financial Officer
|
EXHIBIT LIST
Exhibit
|
Description
|
|
|
99.1
|
Presentation – Rodman & Renshaw Global Investment
Conference – September 13, 2016
|
|
|
|
|
|
|
IntelliPharmaCeutics (QB) (USOTC:IPCIF)
Historical Stock Chart
From Mar 2024 to Apr 2024
IntelliPharmaCeutics (QB) (USOTC:IPCIF)
Historical Stock Chart
From Apr 2023 to Apr 2024